The demand for factor VIII and for factor IX and the toll fractionation product surplus management.
作者信息
Calizzani Gabriele, Profili Samantha, Candura Fabio, Lanzoni Monica, Vaglio Stefania, Cannata Livia, Liumbruno Giancarlo M, Franchini Massimo, Mannucci Pier Mannuccio, Grazzini Giuliano
机构信息
Italian National Blood Centre, National Institute of Health, Rome, Italy.
Italian National Blood Centre, National Institute of Health, Rome, Italy Scientific Direction, IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy.
出版信息
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
Abstract
摘要
相似文献
1
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.对凝血因子 VIII、凝血因子 IX 的需求以及凝血因子浓缩物产品过剩管理。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
2
Clinical use of factor VIII and factor IX concentrates.凝血因子VIII和凝血因子IX浓缩物的临床应用。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
3
Letter: Blood fractions for haemophilia.信件：血友病的血液成分
Lancet. 1974 Dec 14;2(7894):1452. doi: 10.1016/s0140-6736(74)90110-x.
4
Production of antihemophilic factor in France.法国抗血友病因子的生产。
Scand J Haematol Suppl. 1984;40:499-503. doi: 10.1111/j.1600-0609.1984.tb02608.x.
5
Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.近期治疗方面的创新能否弥补自给自足政策中明显的不足？
Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S81-4. doi: 10.1097/00001721-199412004-00021.
6
Prophylaxis for adults with haemophilia: one size does not fit all.成人血友病的预防：一种方法并不适用于所有人。
Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11.
7
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.IX因子缺乏症患者与VIII因子缺乏症患者治疗情况的比较：作为国际IX因子治疗网络一部分开展的一项国际调查结果
Haemophilia. 2014 Sep;20(5):e362-4. doi: 10.1111/hae.12487. Epub 2014 Aug 25.
8
Factor products in the treatment of hemophilia.血友病治疗中的凝血因子产品。
J Pediatr Health Care. 2004 May-Jun;18(3):156-7. doi: 10.1016/j.pedhc.2004.02.008.
9
[Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].[西班牙血友病治疗中的血液衍生物。当前及未来需求]
Sangre (Barc). 1979;24(5-C):942-6.
10
Prophylaxis in haemophilia should be life-long.血友病的预防应该是终身的。
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
引用本文的文献
1
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?用于治疗出血性疾病的产品的病原体去除/灭活：有哪些工艺，我们应该对患者说些什么？
Ann Hematol. 2017 Aug;96(8):1253-1270. doi: 10.1007/s00277-017-3028-4. Epub 2017 Jun 18.
2
Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.预防和减少遗传性出血性疾病对健康和社会影响的组织模式定义。
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s582-8. doi: 10.2450/2014.0087-14s.
3
Uncovered needs in the management of inherited bleeding disorders in Italy.意大利遗传性出血性疾病管理中未被满足的需求。
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s563-6. doi: 10.2450/2014.0036-14s.
4
Present and future challenges in the treatment of haemophilia: the patient's perspective.血友病治疗中的当前与未来挑战：患者视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
5
Plasma-derived medicinal products: demand and clinical use.血浆衍生药物产品：需求与临床应用。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s2-5. doi: 10.2450/2013.002s.
6
Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.血浆及血浆衍生药品的自给自足：意大利的情况
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s118-31. doi: 10.2450/2013.018s.
7
Public expenditure for plasma-derived and recombinant medicinal products in Italy.意大利用于血浆衍生和重组药物产品的公共支出。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s110-7. doi: 10.2450/2013.017s.
本文引用的文献
1
The evolution of the regulatory framework for the plasma and plasma-derived medicinal products system in Italy.意大利血浆及血浆衍生药品体系监管框架的演变
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s6-12. doi: 10.2450/2013.003s.
2
Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.血浆采集、合同分馏及血浆衍生药品生产公共系统的可持续性。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s138-47. doi: 10.2450/2013.020s.
3
Plasma-derived medicinal products in Italy: information sources and flows.意大利的血浆源性药品：信息来源与流通
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s13-7. doi: 10.2450/2013.004s.
4
Hemophilia A in the third millennium.血友病 A 在第三个千年。
Blood Rev. 2013 Jul;27(4):179-84. doi: 10.1016/j.blre.2013.06.002. Epub 2013 Jun 28.
5
Haemophilia care in Europe - a survey of 35 countries.欧洲血友病护理 - 35 个国家的调查。
Haemophilia. 2013 Jul;19(4):e239-47. doi: 10.1111/hae.12125. Epub 2013 Apr 4.
6
Treatment of hemophilia B: focus on recombinant factor IX.乙型血友病的治疗：聚焦于重组凝血因子IX。
Biologics. 2013;7:33-8. doi: 10.2147/BTT.S31582. Epub 2013 Feb 12.
7
Expert Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary non-remunerated blood donation (VNRBD).实现安全血液和血液制品自给自足的专家共识声明，基于自愿无偿献血（VNRBD）。
Vox Sang. 2012 Nov;103(4):337-42. doi: 10.1111/j.1423-0410.2012.01630.x. Epub 2012 Jun 13.
8
Past, present and future of hemophilia: a narrative review.血友病的过去、现在和未来：叙事性综述。
Orphanet J Rare Dis. 2012 May 2;7:24. doi: 10.1186/1750-1172-7-24.
9
How we choose factor VIII to treat hemophilia.我们如何选择因子 VIII 治疗血友病。
Blood. 2012 May 3;119(18):4108-14. doi: 10.1182/blood-2012-01-394411. Epub 2012 Mar 12.
10
Prophylaxis in haemophilia should be life-long.血友病的预防应该是终身的。
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
Zotero 插件